How this company measures up on the fundamentals that matter
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $203, 39% above fair value of $146. Strong competitive moat. 27% profit margins. Passes all ethical screens. Ranks better than 69% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-07 | FARRELL MICHAEL J | Chief Executive Officer | 4,991 | $730,383 | |
| 2026-05-07 | FARRELL MICHAEL J | Chief Executive Officer | 4,991 | $1,037,233 | |
| 2026-04-07 | FARRELL MICHAEL J | Chief Executive Officer | 4,991 | $730,383 | |
| 2026-04-07 | FARRELL MICHAEL J | Chief Executive Officer | 4,991 | $1,125,486 | |
| 2026-04-01 | FARRELL PETER CRAIG | Director | 2,000 | $450,000 | |
| 2026-04-01 | SANDERCOCK BRETT | Chief Financial Officer | 1,000 | $224,310 | |
| 2026-03-09 | FARRELL MICHAEL J | Chief Executive Officer | 4,991 | $730,383 | |
| 2026-03-09 | FARRELL MICHAEL J | Chief Executive Officer | 4,991 | $1,252,902 | |
| 2026-03-04 | FARRELL PETER CRAIG | Director | 2,000 | $520,440 | |
| 2026-03-02 | SANDERCOCK BRETT | Chief Financial Officer | 1,000 | $254,300 |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15